Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDTX Cidara Therapeutics	$49.45 +3.0%	$25.04	$10.14 ▼ $56.83	$603.78M	0.79	166,729 shs	3.75 million shs
DRUG Bright Minds Biosciences	$23.27 -6.1%	$29.56	$0.93 ▼ $79.02	$163.82M	-5.74	825,037 shs	627,261 shs
HUMA Humacyte	$2.12 -4.5%	$2.06	$1.15 ▼ $9.79	$328.85M	1.99	3.81 million shs	7.26 million shs
PMVP PMV Pharmaceuticals	$1.07 -0.9%	$0.98	$0.81 ▼ $2.80	$55.59M	1.43	196,353 shs	97,677 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDTX Cidara Therapeutics	0.00%	+135.25%	+124.16%	+129.57%	+314.15%
DRUG Bright Minds Biosciences	0.00%	-14.79%	-10.50%	-35.49%	+2,045.49%
HUMA Humacyte	0.00%	-8.23%	-20.90%	+24.34%	-55.83%
PMVP PMV Pharmaceuticals	0.00%	-1.83%	+23.56%	-1.83%	-33.95%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CDTX Cidara Therapeutics	3.7949 of 5 stars	3.6	2.0	4.6	3.1	0.0	0.0
DRUG Bright Minds Biosciences	3.1825 of 5 stars	3.6	3.0	0.0	4.0	2.5	0.0
HUMA Humacyte	2.6739 of 5 stars	3.5	3.0	0.0	1.4	2.5	0.6
PMVP PMV Pharmaceuticals	2.9725 of 5 stars	3.5	3.0	0.0	3.3	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CDTX Cidara Therapeutics	3.11	Buy	$55.43	12.09% Upside
DRUG Bright Minds Biosciences	3.25	Buy	$83.25	257.76% Upside
HUMA Humacyte	3.00	Buy	$11.71	452.56% Upside
PMVP PMV Pharmaceuticals	3.00	Buy	$5.50	414.02% Upside

Current Analyst Ratings Breakdown

Latest PMVP, CDTX, HUMA, and DRUG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	CDTX Cidara Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/24/2025	CDTX Cidara Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$35.00 ➝ $75.00
6/24/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$50.00 ➝ $68.00
6/23/2025	CDTX Cidara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$41.00 ➝ $53.00
6/23/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$36.00 ➝ $54.00
6/23/2025	CDTX Cidara Therapeutics	WBB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy	$45.00
6/18/2025	CDTX Cidara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$41.00
6/10/2025	CDTX Cidara Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
6/9/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/4/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$35.00 ➝ $36.00
6/2/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$47.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CDTX Cidara Therapeutics	$1.27M	475.42	N/A	N/A	$14.92 per share	3.31
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	$0.92 per share	N/A
HUMA Humacyte	$1.57M	209.46	N/A	N/A	($0.41) per share	-5.17
PMVP PMV Pharmaceuticals	N/A	N/A	N/A	N/A	$3.40 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CDTX Cidara Therapeutics	-$169.83M	-$29.47	N/A	N/A	N/A	N/A	-73.04%	-54.28%	8/12/2025 (Estimated)
DRUG Bright Minds Biosciences	-$2.06M	-$0.36	N/A	N/A	N/A	N/A	-14.56%	-14.29%	8/13/2025 (Estimated)
HUMA Humacyte	-$148.70M	-$0.69	N/A	N/A	N/A	N/A	N/A	-73.59%	8/12/2025 (Estimated)
PMVP PMV Pharmaceuticals	-$58.71M	-$1.18	N/A	N/A	N/A	N/A	-32.54%	-29.59%	8/6/2025 (Estimated)

Latest PMVP, CDTX, HUMA, and DRUG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q2 2025	DRUG Bright Minds Biosciences	-$0.39	-$0.29	+$0.10	-$0.29	N/A	N/A
5/13/2025	Q1 2025	HUMA Humacyte	-$0.19	-$0.10	+$0.09	$0.28	$0.46 million	$0.52 million
5/9/2025	Q1 2025	PMVP PMV Pharmaceuticals	-$0.37	-$0.34	+$0.03	-$0.34	N/A	N/A
5/8/2025	Q1 2025	CDTX Cidara Therapeutics	-$5.45	-$1.66	+$3.79	-$1.66	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	N/A
HUMA Humacyte	N/A	N/A	N/A	N/A	N/A
PMVP PMV Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CDTX Cidara Therapeutics	N/A	3.87	3.87
DRUG Bright Minds Biosciences	N/A	126.01	126.01
HUMA Humacyte	0.36	3.68	3.28
PMVP PMV Pharmaceuticals	N/A	16.75	16.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CDTX Cidara Therapeutics	35.82%
DRUG Bright Minds Biosciences	40.52%
HUMA Humacyte	44.71%
PMVP PMV Pharmaceuticals	90.20%

Insider Ownership

Company	Insider Ownership
CDTX Cidara Therapeutics	7.64%
DRUG Bright Minds Biosciences	42.66%
HUMA Humacyte	5.10%
PMVP PMV Pharmaceuticals	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CDTX Cidara Therapeutics	90	12.21 million	11.28 million	No Data
DRUG Bright Minds Biosciences	N/A	7.04 million	4.04 million	Not Optionable
HUMA Humacyte	150	155.12 million	147.21 million	Optionable
PMVP PMV Pharmaceuticals	50	51.95 million	48.01 million	Optionable

PMVP, CDTX, HUMA, and DRUG Headlines

Recent News About These Companies

PMV Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences on Oncology Innovation and Healthcare Advances

May 23, 2025 | quiverquant.comQ

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

May 23, 2025 | globenewswire.com

We're Keeping An Eye On PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Rate

May 18, 2025 | finance.yahoo.com

PMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights

May 9, 2025 | finanznachrichten.de

PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights

May 9, 2025 | finance.yahoo.com

Why PMV Pharmaceuticals, Inc.’s (PMVP) Stock Is Up 7.83%

April 21, 2025 | aaii.comA

Here's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom Fishing

March 5, 2025 | zacks.com

PMV Pharmaceuticals reports FY24 EPS ($1.14), consensus ($1.02)

March 3, 2025 | markets.businessinsider.com

PMV Pharmaceuticals sees cash runway to end of 2026

March 3, 2025 | markets.businessinsider.com

PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights

March 3, 2025 | globenewswire.com

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

February 11, 2025 | globenewswire.com

PMV Pharmaceuticals stock hits 52-week low at $1.32

January 21, 2025 | msn.com

PMV Pharmaceuticals files $200M mixed securities shelf

November 21, 2024 | markets.businessinsider.com

PMV Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer

November 9, 2024 | markets.businessinsider.com

PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results

November 7, 2024 | markets.businessinsider.com

Oppenheimer Sticks to Its Hold Rating for PMV Pharmaceuticals (PMVP)

October 25, 2024 | markets.businessinsider.com

PMV Pharmaceuticals (PMVP) Gets a Buy from Craig-Hallum

October 25, 2024 | markets.businessinsider.com

PMV Pharmaceuticals Provides a Progress Update on PYNNACLE Clinical Trial

October 23, 2024 | finance.yahoo.com

PMV provides update on Phase 2, Phase 1b portions of PYNNACLE trial

October 23, 2024 | markets.businessinsider.com

PMV Pharma (NASDAQ:PMVP) Stock Quotes, Forecast and News Summary

October 8, 2024 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA
By Leo Miller | June 12, 2025
View IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA

PMVP, CDTX, HUMA, and DRUG Company Descriptions

Cidara Therapeutics NASDAQ:CDTX

$49.45 +1.42 (+2.96%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$48.83 -0.62 (-1.25%)

As of 04:43 AM Eastern

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Bright Minds Biosciences NASDAQ:DRUG

$23.27 -1.51 (-6.09%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$23.62 +0.34 (+1.48%)

As of 04:05 AM Eastern

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Humacyte NASDAQ:HUMA

$2.12 -0.10 (-4.50%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.17 +0.05 (+2.17%)

As of 04:42 AM Eastern

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

PMV Pharmaceuticals NASDAQ:PMVP

$1.07 -0.01 (-0.93%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.80 +1.73 (+161.68%)

As of 04:00 AM Eastern

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time